BioCryst Pharmaceuticals reported $828.6M in Debt for its fiscal quarter ending in December of 2024.





Debt Change Date
Alnylam Pharmaceuticals USD 2.48B 1.21B Sep/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Chugai Pharma JPY 14.11B 1.93B Dec/2022
Daiichi Sankyo JPY 500.48B 200B Jun/2026
DBV Technologies USD 7.5M 1.4M Sep/2026
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Gilead Sciences USD 26.25B 4.07B Jun/2026
GlaxoSmithKline GBP 18.24B 818M Jun/2026
Glaxosmithkline GBP 23.7B 4.65B Sep/2026
Incyte USD 38.27M 1.16M Jun/2026
Ionis Pharmaceuticals USD 1.77B 141M Sep/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Neurocrine Biosciences USD 392.3M 9.5M Sep/2026
Novavax USD 233.31M 4.23M Sep/2024
PTC Therapeutics USD 2.84B 2.15B Sep/2026
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sarepta Therapeutics USD 857.36M 188.48M Sep/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 6.48B 4.5B Sep/2026